{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T21:17:50Z","timestamp":1783372670804,"version":"3.54.6"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82202212"],"award-info":[{"award-number":["82202212"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s11307-026-02083-y","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T16:11:27Z","timestamp":1775059887000},"page":"539-551","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Preclinical Study of Radiolabeled LyP-1 for Detecting Sunitinib-induced Changes in the Tumor Microenvironment and Synergistic Antitumor Effects in Triple-negative Breast Cancer"],"prefix":"10.1007","volume":"28","author":[{"given":"Sisi","family":"Liao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinli","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifang","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiali","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingzhou","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhua","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meilin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningning","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"2083_CR1","doi-asserted-by":"publisher","first-page":"108253","DOI":"10.1016\/j.pharmthera.2022.108253","volume":"237","author":"JY So","year":"2022","unstructured":"So JY, Ohm J, Lipkowitz S, Yang L (2022) Triple negative breast cancer (TNBC): non-genetic tumor heterogeneity and immune microenvironment: emerging treatment options. Pharmacol Ther 237:108253","journal-title":"Pharmacol Ther"},{"key":"2083_CR2","doi-asserted-by":"publisher","first-page":"1441667","DOI":"10.3389\/fimmu.2024.1441667","volume":"15","author":"Y Yang","year":"2024","unstructured":"Yang Y, Li H, Yang W, Shi Y (2024) Improving efficacy of TNBC immunotherapy: based on analysis and subtyping of immune microenvironment. Front Immunol 15:1441667","journal-title":"Front Immunol"},{"key":"2083_CR3","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.3390\/ijms26062795","volume":"26","author":"S Niture","year":"2025","unstructured":"Niture S, Ghosh S, Jaboin J, Seneviratne D (2025) Tumor microenvironment dynamics of triple-negative breast cancer under radiation therapy. Int J Mol Sci 26:2795","journal-title":"Int J Mol Sci"},{"key":"2083_CR4","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.3892\/ijo.2020.5135","volume":"57","author":"KA Won","year":"2020","unstructured":"Won KA, Spruck C (2020) Triple-negative breast cancer therapy: current and future perspectives (Review). Int J Oncol 57:1245\u20131261","journal-title":"Int J Oncol"},{"key":"2083_CR5","doi-asserted-by":"publisher","first-page":"e071674","DOI":"10.1136\/bmj-2022-071674","volume":"381","author":"RA Leon-Ferre","year":"2023","unstructured":"Leon-Ferre RA, Goetz MP (2023) Advances in systemic therapies for triple negative breast cancer. BMJ 381:e071674","journal-title":"BMJ"},{"key":"2083_CR6","doi-asserted-by":"publisher","first-page":"e1481","DOI":"10.1634\/theoncologist.2019-0982","volume":"25","author":"S Zhao","year":"2020","unstructured":"Zhao S, Ma D, Xiao Y et al (2020) Molecular subtyping of triple-negative breast cancers by immunohistochemistry: molecular basis and clinical relevance. Oncologist 25:e1481\u2013e1491","journal-title":"Oncologist"},{"key":"2083_CR7","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1080\/14737140.2021.1840984","volume":"21","author":"J Sukumar","year":"2021","unstructured":"Sukumar J, Gast K, Quiroga D, Lustberg M, Williams N (2021) Triple-negative breast cancer: promising prognostic biomarkers currently in development. Expert Rev Anticancer Ther 21:135\u2013148","journal-title":"Expert Rev Anticancer Ther"},{"key":"2083_CR8","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","volume":"176","author":"RS Apte","year":"2019","unstructured":"Apte RS, Chen DS, Ferrara N (2019) VEGF in signaling and disease: beyond discovery and development. Cell 176:1248\u20131264","journal-title":"Cell"},{"key":"2083_CR9","doi-asserted-by":"publisher","first-page":"2184145","DOI":"10.1080\/15384047.2023.2184145","volume":"24","author":"E Goggins","year":"2023","unstructured":"Goggins E, Mironchik Y, Kakkad S et al (2023) Reprogramming of VEGF-mediated extracellular matrix changes through autocrine signaling. Cancer Biol Ther 24:2184145","journal-title":"Cancer Biol Ther"},{"key":"2083_CR10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","volume":"15","author":"Y Li","year":"2022","unstructured":"Li Y, Zhang H, Merkher Y et al (2022) Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol 15:121","journal-title":"J Hematol Oncol"},{"key":"2083_CR11","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","volume":"8","author":"ZL Liu","year":"2023","unstructured":"Liu ZL, Chen HH, Zheng LL, Sun LP, Shi L (2023) Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduct Target Ther 8:198","journal-title":"Signal Transduct Target Ther"},{"key":"2083_CR12","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.breast.2013.07.037","volume":"22","author":"G Curigliano","year":"2013","unstructured":"Curigliano G, Pivot X, Cortes J et al (2013) Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer. Breast 22:650\u2013656","journal-title":"Breast"},{"key":"2083_CR13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1080\/15384047.2017.1294288","volume":"18","author":"H Sun","year":"2017","unstructured":"Sun H, Zhang D, Yao Z et al (2017) Anti-angiogenic treatment promotes triple-negative breast cancer invasion via vasculogenic mimicry. Cancer Biol Ther 18:205\u2013213","journal-title":"Cancer Biol Ther"},{"key":"2083_CR14","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/nrc2442","volume":"8","author":"G Bergers","year":"2008","unstructured":"Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8:592\u2013603","journal-title":"Nat Rev Cancer"},{"key":"2083_CR15","doi-asserted-by":"publisher","first-page":"4713","DOI":"10.1038\/onc.2014.396","volume":"34","author":"DC Singleton","year":"2015","unstructured":"Singleton DC, Rouhi P, Zois CE et al (2015) Hypoxic regulation of RIOK3 is a major mechanism for cancer cell invasion and metastasis. Oncogene 34:4713\u20134722","journal-title":"Oncogene"},{"key":"2083_CR16","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1158\/1078-0432.CCR-22-1366","volume":"29","author":"SA Patel","year":"2023","unstructured":"Patel SA, Nilsson MB, Le X, Cascone T, Jain RK, Heymach JV (2023) Molecular mechanisms and future implications of VEGF\/VEGFR in cancer therapy. Clin Cancer Res 29:30\u201339","journal-title":"Clin Cancer Res"},{"key":"2083_CR17","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.3390\/cells8091102","volume":"8","author":"J Jaszai","year":"2019","unstructured":"Jaszai J, Schmidt MHH (2019) Trends and challenges in tumor anti-angiogenic therapies. Cells 8:1102","journal-title":"Cells"},{"key":"2083_CR18","first-page":"188427","volume":"1874","author":"MMG Kes","year":"2020","unstructured":"Kes MMG, den Van Bossche J, Griffioen AW, Huijbers EJM (2020) Oncometabolites lactate and succinate drive pro-angiogenic macrophage response in tumors. Biochimica et Biophysica Acta (BBA) 1874:188427","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"key":"2083_CR19","first-page":"333","volume":"72","author":"SP Rowe","year":"2022","unstructured":"Rowe SP, Pomper MG (2022) Molecular imaging in oncology: current impact and future directions. CA Cancer J Clin 72:333\u2013352","journal-title":"CA Cancer J Clin"},{"key":"2083_CR20","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.neo.2018.05.006","volume":"20","author":"CS Wegner","year":"2018","unstructured":"Wegner CS, Hauge A, Simonsen TG, Gaustad JV, Andersen LMK, Rofstad EK (2018) DCE-MRI of sunitinib-induced changes in tumor microvasculature and hypoxia: a study of pancreatic ductal adenocarcinoma xenografts. Neoplasia 20:734\u2013744","journal-title":"Neoplasia"},{"key":"2083_CR21","doi-asserted-by":"publisher","first-page":"959","DOI":"10.2967\/jnumed.109.072199","volume":"51","author":"Z Levashova","year":"2010","unstructured":"Levashova Z, Backer M, Hamby CV, Pizzonia J, Backer JM, Blankenberg FG (2010) Molecular imaging of changes in the prevalence of vascular endothelial growth factor receptor in sunitinib-treated murine mammary tumors. J Nucl Med 51:959\u2013966","journal-title":"J Nucl Med"},{"key":"2083_CR22","doi-asserted-by":"publisher","first-page":"6588","DOI":"10.1158\/1078-0432.CCR-12-1501","volume":"18","author":"JP O'Connor","year":"2012","unstructured":"O\u2019Connor JP, Jayson GC (2012) Do imaging biomarkers relate to outcome in patients treated with VEGF inhibitors? Clin Cancer Res 18:6588\u20136598","journal-title":"Clin Cancer Res"},{"key":"2083_CR23","doi-asserted-by":"publisher","first-page":"4127","DOI":"10.1158\/0008-5472.CAN-17-0248","volume":"77","author":"SP Robinson","year":"2017","unstructured":"Robinson SP, Boult JKR, Vasudev NS, Reynolds AR (2017) Monitoring the vascular response and resistance to Sunitinib in renal cell carcinoma in vivo with susceptibility contrast MRI. Cancer Res 77:4127\u20134134","journal-title":"Cancer Res"},{"key":"2083_CR24","doi-asserted-by":"publisher","first-page":"9381","DOI":"10.1073\/pnas.0403317101","volume":"101","author":"P Laakkonen","year":"2004","unstructured":"Laakkonen P, \u00c5kerman ME, Biliran H et al (2004) Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Proc Natl Acad Sci USA 101:9381\u20139386","journal-title":"Proc Natl Acad Sci USA"},{"key":"2083_CR25","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1080\/10717544.2019.1587047","volume":"26","author":"N Song","year":"2019","unstructured":"Song N, Zhao L, Zhu M, Zhao J (2019) Recent progress in LyP-1-based strategies for targeted imaging and therapy. Drug Deliv 26:363\u2013375","journal-title":"Drug Deliv"},{"key":"2083_CR26","doi-asserted-by":"publisher","first-page":"18682","DOI":"10.18632\/oncotarget.24588","volume":"9","author":"L Sim\u00f3n-Gracia","year":"2018","unstructured":"Sim\u00f3n-Gracia L, Scodeller P, Fuentes SS et al (2018) Application of polymersomes engineered to target p32 protein for detection of small breast tumors in mice. Oncotarget 9:18682\u201318697","journal-title":"Oncotarget"},{"key":"2083_CR27","doi-asserted-by":"publisher","first-page":"7210","DOI":"10.1158\/0008-5472.CAN-07-6752","volume":"68","author":"V Fogal","year":"2008","unstructured":"Fogal V, Zhang L, Krajewski S, Ruoslahti E (2008) Mitochondrial\/cell-surface protein p32\/gC1qR as a molecular target in tumor cells and tumor stroma. Cancer Res 68:7210\u20137218","journal-title":"Cancer Res"},{"key":"2083_CR28","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jconrel.2016.07.020","volume":"238","author":"ZG She","year":"2016","unstructured":"She ZG, Hamzah J, Kotamraju VR, Pang HB, Jansen S, Ruoslahti E (2016) Plaque-penetrating peptide inhibits development of hypoxic atherosclerotic plaque. J Control Release 238:212\u2013220","journal-title":"J Control Release"},{"key":"2083_CR29","doi-asserted-by":"publisher","first-page":"7154","DOI":"10.1073\/pnas.1104540108","volume":"108","author":"J Hamzah","year":"2011","unstructured":"Hamzah J, Kotamraju VR, Seo JW et al (2011) Specific penetration and accumulation of a homing peptide within atherosclerotic plaques of apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A 108:7154\u20137159","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2083_CR30","doi-asserted-by":"publisher","first-page":"5167","DOI":"10.2147\/IJN.S312238","volume":"16","author":"J Zhu","year":"2021","unstructured":"Zhu J, Yang J, Zhao L et al (2021) (131)I-labeled multifunctional polyethylenimine\/doxorubicin complexes with pH-controlled cellular uptake property for enhanced SPECT imaging and chemo\/radiotherapy of tumors. Int J Nanomedicine 16:5167\u20135183","journal-title":"Int J Nanomedicine"},{"key":"2083_CR31","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.cell.2007.04.019","volume":"129","author":"B Keith","year":"2007","unstructured":"Keith B, Celeste SM (2007) Hypoxia-inducible factors, stem cells, and cancer. Cell 129:465\u2013472","journal-title":"Cell"},{"key":"2083_CR32","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nrclinonc.2011.83","volume":"8","author":"K De Bock","year":"2011","unstructured":"De Bock K, Mazzone M, Carmeliet P (2011) Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not? Nat Rev Clin Oncol 8:393\u2013404","journal-title":"Nat Rev Clin Oncol"},{"key":"2083_CR33","doi-asserted-by":"publisher","first-page":"9502712","DOI":"10.1155\/2019\/9502712","volume":"2019","author":"N Song","year":"2019","unstructured":"Song N, Zhao L, Zhu M, Zhao J (2019) 99m)Tc-labeled LyP-1 for SPECT imaging of triple negative breast cancer. Contrast Media Mol Imaging 2019:9502712","journal-title":"Contrast Media Mol Imaging"},{"key":"2083_CR34","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3760\/cma.j.issn.0366-6999.20112546","volume":"126","author":"M-m Yu","year":"2013","unstructured":"Yu M-m, Wang R-f, Chen Y-h, Zhou H-z, Deng X-h (2013) Radiolabeling LyP-1 peptide and preliminary biodistribution evaluation in mice bearing MDA-MB-435 xenografts. Chin Med J 126:471\u2013475","journal-title":"Chin Med J"},{"key":"2083_CR35","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.trecan.2017.05.002","volume":"3","author":"S Rey","year":"2017","unstructured":"Rey S, Schito L, Wouters BG, Eliasof S, Kerbel RS (2017) Targeting hypoxia-inducible factors for antiangiogenic cancer therapy. Trends Cancer 3:529\u2013541","journal-title":"Trends Cancer"},{"key":"2083_CR36","doi-asserted-by":"publisher","first-page":"5260","DOI":"10.1158\/1078-0432.CCR-06-0517","volume":"12","author":"I Serganova","year":"2006","unstructured":"Serganova I, Humm J, Ling C, Blasberg R (2006) Tumor hypoxia imaging. Clin Cancer Res 12:5260\u20135264","journal-title":"Clin Cancer Res"},{"key":"2083_CR37","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13550-017-0324-x","volume":"7","author":"T Puri","year":"2017","unstructured":"Puri T, Greenhalgh TA, Wilson JM et al (2017) [(18)F]Fluoromisonidazole PET in rectal cancer. EJNMMI Res 7:78","journal-title":"EJNMMI Res"},{"key":"2083_CR38","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.addr.2016.07.012","volume":"113","author":"Z Zhou","year":"2017","unstructured":"Zhou Z, Lu ZR (2017) Molecular imaging of the tumor microenvironment. Adv Drug Deliv Rev 113:24\u201348","journal-title":"Adv Drug Deliv Rev"},{"key":"2083_CR39","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1089\/hum.2020.078","volume":"31","author":"W Xu","year":"2020","unstructured":"Xu W, Yang Y, Hu Z et al (2020) LyP-1-modified oncolytic adenoviruses targeting transforming growth factor beta inhibit tumor growth and metastases and augment immune checkpoint inhibitor therapy in breast cancer mouse models. Hum Gene Ther 31:863\u2013880","journal-title":"Hum Gene Ther"},{"key":"2083_CR40","doi-asserted-by":"publisher","first-page":"e2302834","DOI":"10.1002\/smll.202302834","volume":"19","author":"K Luo","year":"2023","unstructured":"Luo K, Yang L, Yan C et al (2023) A dual-targeting liposome enhances triple-negative breast cancer chemoimmunotherapy through inducing immunogenic cell death and inhibiting STAT3 activation. Small 19:e2302834","journal-title":"Small"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-026-02083-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11307-026-02083-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-026-02083-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T21:09:35Z","timestamp":1783372175000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11307-026-02083-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2083"],"URL":"https:\/\/doi.org\/10.1007\/s11307-026-02083-y","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"value":"1536-1632","type":"print"},{"value":"1860-2002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"assertion":[{"value":"25 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no potential conflicts of interest relevant to this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}